Rheumatoid Nodules: Treatment Options, Removal & Management

Managing Rheumatoid Nodules

Rheumatoid nodules are firm, subcutaneous lumps occurring in ~25–35% of rheumatoid arthritis (RA) patients, typically over pressure points (elbows, forearms, heels, occiput). They reflect disease severity and are associated with rheumatoid factor (RF) and anti-CCP positivity.

Medical Management

Disease-Modifying Antirheumatic Drugs (DMARDs)

• Methotrexate (MTX): Anchor drug; may reduce nodule size/number. Paradoxically, MTX can induce accelerated nodulosis (new small nodules on fingers) in some patients.
• Other conventional DMARDs: Sulfasalazine, leflunomide, hydroxychloroquine – modest effect on nodules.
• Biologic DMARDs: TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 inhibitor (tocilizumab), B-cell depletion (rituximab), T-cell costimulation blocker (abatacept), JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Biologics often regress nodules with systemic disease control.

Corticosteroids

• Systemic: Bridge therapy for flares; not for long-term nodule management.
• Intralesional injection: Triamcinolone acetonide 5–10 mg/mL into nodule → shrinkage in 60–80%. Risk: skin atrophy, depigmentation, tendon rupture (if near tendon).

NSAIDs

Symptomatic relief for pain/inflammation; no effect on nodule size.

Non-Pharmacologic Measures

• Pressure relief: Elbow pads, cushioned footwear, ergonomic modifications.
• Splinting/immobilization: Reduces mechanical irritation at joints.
• Physical therapy: Maintains ROM, strengthens surrounding musculature.
• Occupational therapy: Adaptive equipment, joint protection techniques.

Surgical Excision

Indication	Considerations
Painful, limiting function	Best outcomes; excision with wide margins to reduce recurrence
Ulceration, infection, fistula	Urgent; may need debridement + antibiotics first
Nerve compression (e.g., ulnar at elbow)	Neurolysis + nodule excision
Cosmetic concern	Discuss scar vs. nodule; recurrence rate 15–30%

Surgical pearls: Excise with capsule; avoid extensor tendon damage; postoperative splinting; control RA activity pre/post-op to reduce recurrence.

Emerging / Adjunctive Therapies

• Rituximab: Particularly effective for nodulosis (anti-CD20 depletes B-cells driving RF).
• Tocilizumab: IL-6 blockade → rapid nodule regression in case series.
• Topical JAK inhibitors (ruxolitinib cream): Early trials for cutaneous RA manifestations.
• Colchicine: Anti-inflammatory; anecdotal for nodules.

Key Points

• Nodules themselves are benign but mark severe/erosive RA.
• Systemic disease control is primary treatment; nodules often improve with it.
• Intralesional steroids for symptomatic isolated nodules.
• Surgery for mechanical complications; recurrence common if RA active.
• MTX-induced nodulosis ≠ treatment failure; may switch/add biologic.
• No cure for RA; goal is remission/low disease activity.

Discuss nodule management within your overall RA treatment plan with your rheumatologist.